Vanda Pharmaceuticals | VNDA - Koszty Sprzedaży I Administracji





Koszty Sprzedaży I Administracji Zmiana Data
Acadia Pharmaceuticals USD 146.88M 1.69M 2026-09
Agios Pharmaceuticals USD 51.55M 13.09M 2026-06
Akebia Therapeutics USD 23.53M 3.19M 2025-12
Alnylam Pharmaceuticals USD 342M 5.92M 2026-09
Anika Therapeutics USD 10.01M 14K 2025-12
Arrowhead Research USD 46.63M 4.88M 2026-06
AstraZeneca USD 4.07B 1.73B 2026-09
Bristol-Myers Squibb USD 1.7B 127M 2026-09
Eli Lilly USD 3.12B 305M 2026-09
Enanta Pharmaceuticals USD -1.05 0.31 2024-12
Halozyme Therapeutics USD 58.24M 1.24M 2026-09
Heron Therapeutics USD 23.74M 605K 2025-12
Insmed USD 253.03M 5.56M 2026-09
J&J USD 6.25B 168M 2026-09
Lexicon Pharmaceuticals USD 3.98M 195K 2025-12
Ligand Pharmaceuticals USD 72.62M 43.49M 2026-09
Merck USD 2.86B 25M 2026-09
Minerva Neurosciences USD 2.48M 58.79K 2024-09
Moderna USD 282M 66M 2026-09
Novartis USD 3.08B 58M 2026-09
Pfizer USD 3.28B 132M 2026-09
PTC Therapeutics USD 80.63M 6.74M 2026-06
Puma Biotechnology USD 16.82M 8.15M 2024-09
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sanofi EUR 2.31B 325M 2026-09
Takeda JPY 271.71B 14.8B 2026-09
Teva Pharmaceutical Industries USD 1.01B 27M 2026-09
Ultragenyx Pharmaceutical USD 97M 9M 2026-09
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12
Veracyte USD 57.95M 2.25M 2026-09